Insulin glargine: the first clinically useful extended-action insulin analogue

Bibliography

• THE DIABETES CONTROL AND COMPLICATIONS TRIAL RESEARCH GROUP: The effect of intensive treatment of diabetes on the development and progression of long-term complications in insulin-dependent diabetes mellitus. N Erigl j Med. (1993) 329:977–986.
   PubMed Web of Science ®Google Scholar
• BARNETT A, OWENS S: Insulin analogues. Lancet (1997) 349:47–51.
   PubMed Web of Science ®Google Scholar
• ZINMAN B: The physiologic replacement of insulin: An elusive goal. N Erigl j Med. (1989) 321:363–370.
   PubMed Web of Science ®Google Scholar
• HOME P: Insulin glargine: the first clinically useful extended acting insulin in half a century? Expert Opiri. Irivestig. Drugs (1999) 8:307–314.
   PubMedGoogle Scholar
• STARKE A, HEINEMANN L, A, BERGER M: The action profiles of human NPH insulin preparations. Dialler Med. (1989) 6:239–244.
   Google Scholar
• OWENS D, JONES IR, BIRTWELL AJ et al.: Study of porcine and human isophane (NPH) insulins in normal subjects. Diabetologia (1984) 26:261–265.
   PubMedGoogle Scholar
• GALLOWAY J, CHANCE R: Improving therapy: achievements and targets. Hormone Metab. Res. (1994)26:591–598.
   PubMed Web of Science ®Google Scholar
• HEINEMANN L, RICHTER B: Clinical pharmacology of human insulin. Diabetes Care 16:90–100 (1993).
   PubMedGoogle Scholar
• LAURITZEN T, FABER O, BINDER C: Variation in 125I-insulin absorption and blood glucose concentration. Diabetologia (1979) 17:291–295.
   PubMed Web of Science ®Google Scholar
• JEHLE P, MICHELER C, JEHLE D, BREITIG D, BOEHM B: Inadequate suspension of neutral protamine Hagedorn (NPH) insulin in pens. Lancet (1999) 354:1604–1607.
   PubMed Web of Science ®Google Scholar
• JORGENSEN S, VAAG A, LANGKJAER, HOUGAARD E MARKUSSEN J: NovoSol Basal: pharmacokinetics of a novel soluble long acting insulin analogue. Br. Med. J. (1989) 299:415–419.
   PubMed Web of Science ®Google Scholar
• MARKUSSEN J, HAVELUND S, KURTZHALS P et al.: Soluble, fatty acid acylated insulins bind to albumin and show protracted action in pigs. Diabetologia (1996) 39:281–288.
   PubMed Web of Science ®Google Scholar
• ROSSKAMP R, PARK G: Long-acting insulin analogs. Diabetes Care (1999) 22:B109–B113.
   Google Scholar
• HEINEMANN L, SINHA K, WEYER C, LOFTAGER M, HIRSCHBEGER S, HEISE T: Time-action profile of the soluble, fatty acid acylated, long-acting analogue NN304. Dialler Med. (1999) 16:332–338.
   Google Scholar
• HORDERN S, WRIGHT J, UMPLEBY A, SHOJAEEMORADIE E RUSSELL-JONES D: A randomised three period crossover trial investigating the effect of subcutaneous insulin detemir and human insulin on glucose metabolism in healthy subjects. Diabet. Med. (2001) 18:82.
   Google Scholar
• STRANGE P, MCGILL J, MAZZEO M:Reduced pharmacokinetic (PK) variability of a novel, long-acting insulin analogue. Diabetes (1999) 48:A103.
   Google Scholar
• LEPORE M, BAROCCI L, FANELLI C, PAMPANELLI S, PORCELLATI F, BOLLI GB: Effect of adequate vs. inadequate resuspension of NPH insulin prior to s.c. injection on pharmacokinetics and -dynamics in T1DM. Diabetologia (2001) 44\(Suppl. 1):A25.
   Google Scholar
• HOWEY D, WOODWORTH J, BOWSHER R, REVIERGO J: Pharmacokinetic and glucodynamic assessments of M-Palmitol Lys (B29) human insulin in healthy volunteers. Diabetologia (1997) A354.
   Google Scholar
• MYERS S, YAKUBU-MADUS FE, JOHNSON WT et al: Acylation of human insulin with palmitic acid extends the time action of human insulin in diabetic dogs. Diabetes (1997) 46:637–642.
   PubMed Web of Science ®Google Scholar
• STAMMBERGER I, TROSCHAU G, DONAUBAUER H: Insulin glargine is not carcinogenic in rats and mice. Diabetes (2001) 50\(Suppl. 2):A429.
   Google Scholar
• BERCHTOLD H, HILGENFELD R: Binding of phenol to R6 insulin hexamers. Biopolymers (Peptide Science) (1999) 51:165–172.
   PubMed Web of Science ®Google Scholar
• SEIPKE G, GEISEN K, NEUBAUER HP,PITTUS C, ROSSKAMP R, SCHWABE: New insulin preparations with prolonged action profiles: A21-modified arginine insulins. Diabetologia (1992) 35\(Supp1.1):A6.
   Google Scholar
• DRYER M PEIN M, SCHMIDT C, HEIDTMANN B, SCHLINZEN M, ROBKAMP D: Comparison of the pharmacokineticsidynamics of Gly(A21) Arg(B21, B32) human insulin (HOE71GT) with NPH insulin following subcutaneous injection by using euglycaemic clamp technique. (1994) 37:A78.
   Google Scholar
• COATES P, MUKHERJEE US, LUZIO S et al.: Pharmacokinetics of a 'long-acting' human insulin analogue (HOE 901) in healthy subjects. Diabetes (1995) 44:130A.
   Google Scholar
• OWENS D, COATES P, LUZIO S, TINBERGEN J, KURTZHALS R: Pharmacokinetics of 1251-labelled insulin glargine (HOE 901) in healthy men. Diabetes Care (2000) 23:813–819.
   PubMed Web of Science ®Google Scholar
• LINKESCHOWA R, HEISE T, REVE K, HUMPESCH B, SEDLACK M, HEINEMANN L: Time-action profile of the long-acting insulin analogue HOE 901. Diabetes (1998) 48:A97.
   Google Scholar
• RAVE K, HEISE T, HEINEMANN L: Time-action profile of insulin glargine (HOE 901) in Japanese volunteers. Diabetes (2000) 49:A363.
   Google Scholar
• SOON P, MATTHEWS D, ROSSKAMP R, HERZ M, KURTZHALS R: Profile of action of biosynthetic long-acting insulin (HOE901) tested in normal volunteers by glucose clamp methodology. Diabetes (1997) 46:161A.
   PubMedGoogle Scholar
• HEINEMANN L, LINKESCHOVA R, RAVE K, HOMPESCH B, SEDLAK M, HEISE T: Time-action profile of the long-acting insulin analog insulin glargine (HOE 901) in comparison with those of nph insulin and placebo. Diabetes Care (2000) 23:644–649.
   PubMed Web of Science ®Google Scholar
• SCHOLTZ H, NIEKERK NV, MEYER B, ROSENKRANZ B: An assessment of the variability in the pharmacodynamics (glucose lowering effect) of HOE 901 compared to NPH and ultralente human insulins using the euglycaemic clamp technique. Diabetologia (1999) 42:A235.
   Google Scholar
• LEPORE M, KURZHALS R, S, FANELLI C, BOLLI G: Pharmacokinetics and dynamics of s.c. injection of the long-acting insulin glargine (HOE 901) in T1DM. Diabetes (1998) 48:A97.
   Google Scholar
• LEPORE M, PAMONELLI S, FANELLI et al. Pharmacokinetics and pharmacodynamics of subcutaneous injection of long-acting human insulin analog glargine, NPH insulin, and ultralente insulin and continuous subcutaneous infusion of insulin lispro. Diabetes (2000) 49:2142–2148.
   PubMed Web of Science ®Google Scholar
• LUZIO S, OWENS D, EVANS M, OGUNKU A, BECK P, KURZHALS R: Comparison of the sc. absorption of HOE 901 and NPH human insulin in Type 2 diabetic subjects. Diabetes (1998) 48:A111.
   Google Scholar
• PIEBER T, EUGENE-JOLCHINE I, DEROBERT E: Efficacy and safety of HOE 901 versus NPH insulin in patients with Type 1 diabetes. Diabetes Care (2000) 23:157–162.
   PubMed Web of Science ®Google Scholar
• •Insulin glargine in Type 1 Diabetics improves fasting blood glucose and reduces nocturnal hypoglycaemia.
   Google Scholar
• ROSENSTOCK J, PARK G, J: Basal insulin glargine (HOE 901) sersusNPH insulin in patients with Type 1 diabetes on multiple daily insulin regimens. Diabetes Care (2000) 23:1137–1142.
   PubMed Web of Science ®Google Scholar
• RATNER RE, HIRSCH IB, NEIFING JL, SK, MECCA TE, WILSON CA: Less hypoglycaemia with insulin glargine in intensive insulin therapy for Type 1 diabetes. Diabetes Care (2000) 23:639–643.
   PubMed Web of Science ®Google Scholar
• •Insulin glargine reduces hypoglycaemia and improves fasting plasma glucose in Type 1 diabetics.
   Google Scholar
• RASKIN P, KLAFF L, BERGENSTAL R, HELLE JP, DONLEY D, MECCA T: A 16-week comparison of the novel insulin analog insulin glargine (HOE 901) and NPH human insulin used with insulin lispro in patients with Type 1 diabetes. Diabetes Care (2000) 23: 1666-1671.
   Google Scholar
• ••Insulin glargine in combination withinsulin lispro improves fasting blood glucose and reduces variability of fasting blood glucose.
   Google Scholar
• MATTHEWS D, PFEIFFER C: A new long-acting insulin (HOE 901) less nocturnal hypoglycaemia when compared with protamine insulin in a clinical trial. Diabetologia (1998) 41:948.
   Google Scholar
• SCHOENLE E: Insulin glargine (HOE 901) lowers fasting blood glucose in children with Type 1 diabetes mellitus without increasing the risk of hypoglycaemia. Diabetologia (1999) 42:A235.
   Google Scholar
• MOHN A, STRANG S, WERNICKE-PANTEN K, LANG AM, EDGE JA, DUNGER DB: Nocturnal glucose control and free insulin levels in children with Type 1 diabetes by use of the long-acting insulin HOE 901 as part of a three-injection regimen. Diabetes Care (2000) 23:557–559.
   PubMedGoogle Scholar
• YKI-JARVINEN H, DRESSLER A, ZIEMAN M: less nocturnal hypoglycaemia and better post-dinner glucose control with insulin-glargine compared with bedtime NPH insulin combination therapy in type 2 diabetes. HOE 901/3002 study group. Diabetes Care (2000) 23(8):1130–1136
   Google Scholar
• •Nocturnal blood glucose control is improved in children with insulin glargine.
   Google Scholar
• RASKIN P, PARK G, ZIMMERMAN J: The effect of HOE 901 on glycaemic control in Type 2 diabetes. Diabetes (1998) 48:A103.
   Google Scholar
• ROSENSTOCK J, SCHWARTZ S, CLARK, C, PARK G, DONLEY D, EDWARDS M: Basal insulin therapy in Type 2 diabetes: 28-week comparison of insulin glargine (HOE 901) and NPH. Diabetes Care (2001) 24:631–636.
   PubMed Web of Science ®Google Scholar
• YKI-JARVINEN H, DRESSLER A, ZIEMEN M: Less nocturnal hypoglycaemia and better post-dinner glucose control with bedtime insulin glargine compared with bedtime NPH insulin during insulin combination therapy in Type 2 diabetes. Diabetes Care (2000) 23:1130–1136.
   PubMed Web of Science ®Google Scholar
• ••Insulin glargine in Type 2 diabetic subjectsimproves 24 h blood glucose profile and reduces hypoglycaemia.
   Google Scholar
• WITTHAUS E, BRADLEY C, STEWART J: HOE 901 (insulin glargine) improves satisfaction with intensified insulin treatment for Type 1 diabetes. Diabetologia (1999) 42:A235.
   Google Scholar
• WITTHAUS E, STEWART J, BRADLEY C: Treatment satisfaction and psychological well-being with insulin glargine compared with NPH in patients with Type 1 diabetes. Diabet. Med. (2001) 18. (In Press).
   Google Scholar
• DREJER K: The bioactivity of insulin analogues from in vitro receptor binding to in vivo glucose uptake. Diabetes Metall. Rev (1992) 8:259–286.
   PubMed Web of Science ®Google Scholar
• DIDERIKSEN L, JORGENSEN L, DREJER K: Carcinogenic effect on female rats after 12 months administration of the insulin analogue B10 Asp. Diabetes (1992) 41:143A.
   Google Scholar
• KURTZHALS P, SCHAFFER L, SORENSEN A et al.: Correlations of receptor binding and metabolic and mitogenic potencies of insulin analogs designed for clinical use. Diabetes (2000) 49:999–1005.
   PubMed Web of Science ®Google Scholar
• SEIPKE G, SAND OW J: Effects of insulinglargine, human insulin and the insulin analogue Asp(B10) on the insulin receptor signalling cascade. Diabetes (2001) 50\(Suppl. 2):A130.
   Google Scholar
• BAHR M, KOLTER T, SEIPKE G, ECKEL J: Growth promoting and metabolic activity of the human insulin analogue [G1yA21, ArgB31, ArgB321 (HOE 901) in muscle cells. Eur. Pharinacal. (1997) 320:259–265.
   PubMed Web of Science ®Google Scholar
• ROBERTS A, STANDL E. E, LANG H: Efficacy and safety of 6-month treatment with insulin detemir in Type 1 diabetic patients on a basal/bolus regimen. Diabetalagia (2001) 44\(Suppl. 1):A207.
   Google Scholar
• BERTI L, KELLERER M, B, SEFFER E, SEIPKE G, HARING HU: The long acting human insulin analog HOE 901: Characteristics of insulin signalling in comparison to Asp(B10) and regular insulin. Harm. Metab. Res. (1998) 30:123–129.
   PubMed Web of Science ®Google Scholar
• CIARALDI TP CARTER L, SEIPKE G,MUDLIAR S, HENRY RR: Effects of the long acting insulin analog insulin glargine on cultured human skeletal muscle cells: comparisons to insulin and IGF-1. Diabetes (2001) 50\(Suppl. 2):A417.
   Google Scholar
• THRAILKILL K, QUATTRIN T, BAKER L, KUNTZE JE, COMPTON PG, MARTHA PM, Jr.: Cotherapy with recombinant human insulin-like growth factor 1 and insulin improves glycaemic control in Type 1 diabetes. Diabetes Care (1999) 22:585–592.
   Google Scholar
• FORJANIC-KLAPPROTH J, HOME PD:Progression of retinopathy with insulin glargine or NPH insulin - a multi-trial analysis. Diabetalagia (2001) 44\(Suppl. 1):A287.
   Google Scholar